OUTLINE: This is a multi-center study.~Fludarabine 25 mg/m2 IV over 30 minutes , Days 1, 2, 4~Velcade(given after fludarabine) 1.3 mg/m2 IV push over 3 to 5 seconds, Days 1, 4, 8, 11~Rituximab (given after Velcade) 375 mg/m2 IV piggyback, Day 1~Cycle = 28 days; max 6 cycles~ECOG Performance Status: 0-2~Life Expectancy: Not specified~Hematopoietic:~Absolute neutrophil count (ANC) ≥ 1.5 K/mm3 (ANC > 0.5 K/mm3 if known lymphomatous involvement of the bone marrow).~Platelets ≥ 100 K/mm3 (Platelets >50 K/mm3 if known lymphomatous involvement of the bone marrow).~Hepatic:~Total bilirubin ≤1.5 ULN~Aspartate aminotransferase (AST, SGOT) ≤ 2.5 x ULN~Alanine aminotransferase (ALT, SGPT) ≤ 2.5 x ULN~Renal:~Creatinine < 1.5 x institutional upper limit (ULN) or creatinine clearance ≥ 50 cc/min~Cardiovascular:~No myocardial infarction within 6 months prior to enrollment~No heart failure per New York Heart Association Classification III or IV~No severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia
The purpose of this study is to determine the effectiveness of fludarabine, Velcade, and rituximab treatment regimen in patients with relapsed or refractory follicular non-Hodgkin lymphoma.